618 related articles for article (PubMed ID: 34331067)
1. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
2. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.
Ohbayashi Y; Iwasaki A; Nakai F; Mashiba T; Miyake M
Osteoporos Int; 2020 Mar; 31(3):577-585. PubMed ID: 31768589
[TBL] [Abstract][Full Text] [Related]
3. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
[TBL] [Abstract][Full Text] [Related]
4. Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series.
Yoshiga D; Yoshioka I; Habu M; Sasaguri M; Tominaga K
Br J Oral Maxillofac Surg; 2022 Jun; 60(5):604-609. PubMed ID: 34996629
[TBL] [Abstract][Full Text] [Related]
5. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw.
Anabtawi M; Tweedale H; Mahmood H
Int J Oral Maxillofac Surg; 2021 Apr; 50(4):501-510. PubMed ID: 32800674
[TBL] [Abstract][Full Text] [Related]
6. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw.
Chopra K; Malhan N
Am J Ther; 2020 Jun; 28(4):e469-e477. PubMed ID: 32618592
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Sim IW; Borromeo GL; Tsao C; Hardiman R; Hofman MS; Papatziamos Hjelle C; Siddique M; Cook GJR; Seymour JF; Ebeling PR
J Clin Oncol; 2020 Sep; 38(26):2971-2980. PubMed ID: 32614699
[TBL] [Abstract][Full Text] [Related]
9. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.
Kim KM; Park W; Oh SY; Kim HJ; Nam W; Lim SK; Rhee Y; Cha IH
Osteoporos Int; 2014 May; 25(5):1625-32. PubMed ID: 24554340
[TBL] [Abstract][Full Text] [Related]
10. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
11. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.
Srivastava A; Nogueras Gonzalez GM; Geng Y; Won AM; Cabanillas ME; Naing A; Myers JN; Li Y; Chambers MS
Support Care Cancer; 2021 May; 29(5):2305-2317. PubMed ID: 33190182
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Osteonecrosis of the Jaw.
Yamachika E; Matsubara M; Ikeda A; Matsumura T; Moritani N; Iida S
J Craniofac Surg; 2015 Oct; 26(7):e575-7. PubMed ID: 26468825
[TBL] [Abstract][Full Text] [Related]
14. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
15. The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice.
Yu W; Su J
Oral Dis; 2020 Apr; 26(3):609-620. PubMed ID: 31903673
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan.
Morishita K; Yamada SI; Kawakita A; Hashidume M; Tachibana A; Takeuchi N; Ohbayashi Y; Kanno T; Yoshiga D; Narai T; Sasaki N; Shinohara H; Uzawa N; Miyake M; Tominaga K; Kodani I; Umeda M; Kurita H
J Orthop Sci; 2020 Nov; 25(6):1079-1083. PubMed ID: 32111549
[TBL] [Abstract][Full Text] [Related]
17. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Neal TW; Schlieve T
J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
[TBL] [Abstract][Full Text] [Related]
18. Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis.
Momesso GAC; Lemos CAA; Santiago-Júnior JF; Faverani LP; Pellizzer EP
Oral Maxillofac Surg; 2020 Jun; 24(2):133-144. PubMed ID: 32056052
[TBL] [Abstract][Full Text] [Related]
19. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
20. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
